{"created":"2023-07-27T06:51:15.152794+00:00","id":44604,"links":{},"metadata":{"_buckets":{"deposit":"5b270f97-8049-4c29-af03-d750cee34d58"},"_deposit":{"created_by":18,"id":"44604","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"44604"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00044604","sets":["2812:2813:2816"]},"author_link":["2401","76693"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicVolumeNumber":"2015-04-01 - 2018-03-31","bibliographic_titles":[{"bibliographic_title":"平成29(2017)年度 科学研究費補助金 基盤研究(C) 研究成果報告書"},{"bibliographic_title":"2017 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"多発性骨髄腫症例での微小残存病変（MRD)検出する方法である次世代シークエンサー(NGS)法、マルチパラメーターフローサイトメトリー(MFC)法を確立し、骨髄や自家移植片中のMRD検査を実施した。その結果、MRDが陰性の場合に極めて良好な無増悪生存や全生存となった。その結果に基づいて、NGSとMFCによるMRD検出の臨床的意義を検証する多施設前向き臨床研究(UMIN-CTR ID: UMIN000022238)を開始した。一方、NGSやMFCでMRDが陰性となった極めて深い奏効を達成した多発性骨髄腫症例の血清中で検出される抗X抗体のターゲット抗原Xは、癌精巣抗原の1種であることを明らかにした。","subitem_description_type":"Abstract"},{"subitem_description":"We demonstrated the clinical value of minimal residual disease (MRD) detection in multiple myeloma (MM) patients using next-generation sequencing (NGS) and multiparameter flow cytometry (MFC). When MRD negativity in bone marrow and/or autografts of MM patients was achieved, the progression-free survival and overall survival were dramatically improved.　Based on the results, we have started the clinical study \"Prognostic value of minimal residual disease detection using multiparameter flow cytometry (EuroFlow method) in patients with multiple myeloma who underwent autologous stem cell transplantation: comparison with sequencing-based method (UMIN-CTR ID: UMIN000022238)\". On the other hand, we clarified that anti-X antibody which is detected in the sera of MRD negative MM patients binds to a cancer-testis antigen X.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:15K08644, 研究期間(年度):2015-04-01 - 2018-03-31","subitem_description_type":"Other"},{"subitem_description":"出典：研究課題「次世代シークエンサーと蛋白質アレイを用いた骨髄腫病態解析と新規治療法の開発」課題番号15K08644\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-15K08644/15K08644seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00050945","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=70401932"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=70401932","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K08644/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K08644/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-15K08644/15K08644seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-15K08644/15K08644seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-04-15"}],"displaytype":"detail","filename":"ME-PR-TAKAMATSU-H-kaken 2018-5p.pdf","filesize":[{"value":"90.1 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-TAKAMATSU-H-kaken 2018-5p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/44604/files/ME-PR-TAKAMATSU-H-kaken 2018-5p.pdf"},"version_id":"2c0ddcfc-0c46-47f1-8260-d1350d7223fb"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"次世代シークエンサーと蛋白質アレイを用いた骨髄腫病態解析と新規治療法の開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"次世代シークエンサーと蛋白質アレイを用いた骨髄腫病態解析と新規治療法の開発"},{"subitem_title":"Development of novel treatments of myeloma based on MRD using next-generation sequencing and protein-array assay","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2816"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-04-15"},"publish_date":"2019-04-15","publish_status":"0","recid":"44604","relation_version_is_last":true,"title":["次世代シークエンサーと蛋白質アレイを用いた骨髄腫病態解析と新規治療法の開発"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T13:01:17.573718+00:00"}